Latest News
-

UniQure and FDA No Longer in Alignment on Approval Pathway for AMT-130
In a new press release, uniQure shared that the FDA no longer agrees with their approach for advancing AMT-130, specifically the use of an external control group. The path forward is uncertain, but uniQure remains committed to the HD community.
-

October 2025: This Month in Huntington’s Disease Research
October was an insight-rich month in Huntington’s disease research: additional clarity around uniQure’s AMT-130, mapping how and where HD changes the brain, early mechanistic studies targeting DNA repair, and a major meeting gathering the field.
-

A Map Through Time: Tracking Huntington’s Disease From Birth in the Brain
Why do some brain cells die first in HD? New study shows changes in gene activity begin at birth in mice, especially in striatum & cortex—mapped with spatial & single-cell tools.
-

How Big Is The Huntington’s Disease Iceberg?
We can count how many people are seen in a clinic with Huntington’s disease by genetic testing, but how many people with the gene for HD are never diagnosed by a doctor? A new mathematical approach seeks to revisit this tricky question.
-

Huntington’s Disease Clinical Research Congress 2025 – Day 3
Catch up on all the latest HD news from Day 3 of the Huntington’s Disease Clinical Research Congress in Nashville, USA.
-

Huntington’s Disease Clinical Research Congress 2025 – Day 2
Catch up on all the latest HD news from Day 2 of the Huntington’s Disease Clinical Research Congress in Nashville, USA.
-

Huntington’s Disease Clinical Research Congress 2025 – Day 1
Catch up on all the latest HD news from Day 1 of the Huntington’s Disease Clinical Research Congress in Nashville, USA.
-

Controlling DNA Scanning Machines to Slow Expansion of CAG Repeats
A new study identifies small molecules that target a DNA repair machine, opening a potential path to delay Huntington’s disease onset.
-

2025 HDBuzz Prize: When Good Huntingtin Goes Missing: A Step Toward Designing Safe HD Treatments
We’re proud to announce Gravity Guignard as a 2025 HDBuzz Prize winner! A new study points to one of the reasons why past HD trials might have failed. The good news? This shows the path to safer drugs, getting us closer to effective therapies.

